Antiviral drugs for cytomegalovirus diseases

Antiviral Research

Volumn 71, Issue 2-3 SPEC. ISS., 2006, Pages 154-163

  Biron, Karen K ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Alkoxyalkyl esters of cidofovir; CMV; Foscarnet; Ganciclovir; Novel benzimidazole riboside antiviral drugs; Nucleoside analog; Nucleotide analog; Pyrophosphate analog; Valaciclovir; Valganciclovir

Indexed keywords

2 BROMO 5,6 DICHLORO 1BETA DEXTRO RIBOPYRANOSYL 1H BENZIMIDAZOLE; ACICLOVIR; ANTIVIRUS AGENT; BENZIMIDAVIR; CIDOFOVIR; CMX 001; CYTOVENE IV; FOMIVIRSEN; FOSCARNET; FOSCARNET SODIUM; GANCICLOVIR; GW 1263W94; GW 275175X; HEXADECYLCYLOXYPROPYLCIDOFOVIR; NUCLEOSIDE DERIVATIVE; PENCICLOVIR; TOMEGLOVIR; TRIFLURIDINE; UNCLASSIFIED DRUG; VALACICLOVIR; VALGANCICLOVIR; VIDARABINE;

AIDS PATIENT; ANEMIA; ANTIVIRAL ACTIVITY; BLOOD TOXICITY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION PREVENTION; KIDNEY GRAFT; NEUTROPENIA; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RETINITIS; SHORT SURVEY; THROMBOCYTOPENIA;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; ANTIVIRAL AGENTS; CLINICAL TRIALS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; INFANT, NEWBORN; MALE; MICE; TRANSPLANTATION;

CYTOMEGALOVIRUS; HERPES;

EID: 33747141729     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.05.002     Document Type: Short Survey

References (67)

1. Balfour Jr. H.H. Cytomegalovirus: the troll of transplantation [editorial]. Arch. Intern. Med. 139 (1979) 279-280
2. Beadle J.R., Hartline C., Aldern K.A., Rodriguez N., Harden E., Kern E.R., and Hostetler K.Y. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob. Agents Chemother. 46 (2002) 2381-2386
3. Biron K.K., Harvey R.J., Chamberlain S.C., Good S.S., Smith III A.A., Davis M.G., Talarico C.L., Miller W.H., Ferris R., Dornsife R.E., Stanat S.C., Drach J.C., Townsend L.B., and Koszalka G.W. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole l-riboside with a unique mode of action. Antimicrob. Agents Chemother. 46 (2002) 2365-2372
4. Boeckh M., Leisenring W., Riddell S.R., Bowden R.A., Huang M.L., Myerson D., Stevens-Ayers T., Flowers M.E., Cunningham T., and Corey L. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 101 (2003) 407-414
5. Boivin G., Goyette N., Gilbert C., Roberts N., Macey K., Paya C., Pescovitz M.D., Humar A., Dominguez E., Washburn K., Blumberg E., Alexander B., Freeman R., Heaton N., and Covington E. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J. Infect. Dis. 189 (2004) 1615-1618
6. Bradford R.D., Cloud G., Lakeman A.D., Boppana S., Kimberlin R.J., Demmler G., Sanchez P., Britt W., Soong S., and Whitley R.J. Detection of cytomegalovirus (CMV) DNA by polymerase chain reaction is associated with hearing loss in newborns with symptomatic congenital CMV infection involving the central nervous system. J. Infect. Dis. 191 (2005) 227-233
7. Buerger I., Reefschlaeger J., Bender W., Eckenberg P., Popp A., Weber O., Graeper S., Klenk H.D., Ruebsamen-Waigmann H., and Hallenberger S. A novel non-nucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products. J. Virol. 75 (2001) 9077-9086
8. Cesaro S., Zhou X., Manzardo C., Buonfrate D., Cusinato R., Tridello G., Mengoli C., Palu G., and Messina C. Cidofovir for cytomegalovirus reactivation in pediatric patients after hematopoietic stem cell transplantation. J. Clin. Virol. 34 (2005) 129-132
9. Chou S., Marousek G.I., Senters A.E., Davis M.G., and Biron K.K. Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. J. Virol. 78 (2004) 7124-7130
10. Ciesla S.L., Trahan J., Wan W.B., Beadle J.R., Aldern K.A., Painter G.R., and Hostetler K.Y. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res. 59 (2003) 163-171
11. Cihlar T., Fuller M.D., and Cherrington J.M. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. J. Virol. 72 (1998) 5927-5936
12. Cope A.V., Sweny P., Sabin C., Rees L., Griffiths P.D., and Emery V.C. Quantity of cytomegalovirus viruria is a major risk factor for cytomegalovirus disease after renal transplantation. J. Med. Virol. 52 (1997) 200-205
13. Cvetkovic R.S., and Wellington K. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs 65 (2005) 859-878
14. Cytovene-IV (ganciclovir sodium for intravenous infusion only) and Cytovene (ganciclovir capsules for oral administration only) package insert. Roche Laboratories Inc., 2000.
15. Deayton J.R., Sabin C.A., Johnson M.A., Emery V.C., Wilson P., and Griffiths P.D. Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy. Lancet 363 (2004) 2116-2121
16. De Clercq E., and Field H.J. Antiviral prodrugs-the development of successful prodrug strategies for antiviral chemotherapy. Br. J. Pharmacol. 147 (2006) 1-11
17. De Clercq E., and Holy A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat. Rev. Drug Discov. 4 (2005) 928-940
18. Elion G.B., Furman P.A., Fyfe J.A., de Miranda P., Beauchamp L., and Schaeffer H.J. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc. Natl. Acad. Sci. U.S.A. 74 (1977) 5716-5720
19. Fiddian P., Sabin C.A., and Griffiths P.D. Valacyclovir provides optimum acyclovir exposure for prevention of cytomegalovirus and related outcomes after organ transplantation. J. Infect. Dis. 186 Suppl. 1 (2002) S110-S115
20. Gandhi M.K., and Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect. Dis. 4 (2004) 725-738
21. Gilbert C., and Boivin G. Human cytomegalovirus resistance to antiviral drugs. Antimicrob. Agents Chemother. 49 (2005) 873-883
22. Goodrich J.M., Bowden R.A., Fisher L., Keller C., Schoch G., and Meyers J.D. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann. Intern. Med. 118 (1993) 173-178
23. Griffiths P.D., and Walter S. Cytomegalovirus. Curr. Opin. Infect. Dis. 18 (2005) 241-245
24. Ho E.S., Lin D.C., Mendel D.B., and Cihlar T. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J. Am. Soc. Nephrol. 11 (2000) 383-393
25. Hodson E.M., Jones C.A., Webster A.C., Strippoli G.F., Barclay P.G., Kable K., Vimalachandra D., and Craig J.C. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 365 (2005) 2105-2115
26. Kalil A.C., Levitsky J., Lyden E., Stoner J., and Freifeld A.G. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann. Intern. Med. 143 (2005) 870-881
27. Kimberlin D.W., Lin C.Y., Sanchez P.J., Demmler G.J., Dankner W., Shelton M., Jacobs R.F., Vaudry W., Pass R.F., Kiell J.M., Soong S.J., Whitley R.J., and National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J. Pediatr. 143 (2003) 16-25
28. Komazin G., Ptak R.G., Emmer B.T., Townsend L.B., and Drach J.C. Resistance of human cytomegalovirus to the benzimidazole l-ribonucleoside maribavir maps to UL27. J. Virol. 77 (2003) 11499-11506
29. Krosky P.M., Baek M.C., and Coen D.M. The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J. Virol. 77 (2003) 905-914
30. Krosky P.M., Baek M.C., Jahng W.J., Barrera I., Harvey R.J., Biron K.K., Coen D.M., and Sethna P.B. The human cytomegalovirus UL44 protein is a substrate for the UL97 protein kinase. J. Virol. 77 (2003) 7720-7727
31. Krosky P.M., Underwood M.R., Turk S.R., Feng K.W., Jain R.K., Ptak R.G., Westerman A.C., Biron K.K., Townsend L.B., and Drach J.C. Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56. J. Virol. 72 (1998) 4721-4728
32. Lalezari J.P., Aberg J.A., Wang L.H., Wire M.B., Miner R., Snowden W., Talarico C.L., Shaw S., Jacobson M.A., and Drew W.L. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob. Agents Chemother. 46 (2002) 2969-2976
33. Li C.R., Greenberg P.D., Gilbert M.J., Goodrich J.M., and Riddell S.R. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 83 (1994) 1971-1979
34. Limaye A.P., Corey L., Koelle D.M., Davis C.L., and Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 356 (2000) 645-649
35. Ljungman P., Deliliers G.L., Platzbecker U., Matthes-Martin S., Bacigalupo A., Einsele H., Ullmann J., Musso M., Trenschel R., Ribaud P., Bornhauser M., Cesaro S., Crooks B., Dekker A., Gratecos N., Klingebiel T., Tagliaferri E., Ullmann A.J., Wacker P., and Cordonnier C. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 97 (2001) 388-392
36. Lowance D., Neumayer H.H., Legendre C.M., Squifflet J.P., Kovarik J., Brennan P.J., Norman D., Mendez R., Keating M.R., Coggon G.L., Crisp A., and Lee I.C. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. 1. N. Engl. J. Med. 340 (1999) 1462-1470
37. Marschall M., Freitag M., Suchy P., Romaker D., Kupfer R., Hanke M., and Stamminger T. The protein kinase pUL97 of human cytomegalovirus interacts with and phosphorylates the DNA polymerase processivity factor pUL44. Virology 311 (2003) 60-71
38. Martin D.F., Kuppermann B.D., Wolitz R.A., Palestine A.G., Li H., and Robinson C.A. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. N. Engl. J. Med. 340 (1999) 1063-1070
39. Mattes F.M., Hainsworth E.G., Geretti A.M., Nebbia G., Prentice G., Potter M., Burroughs A.K., Sweny P., Hassan-Walker A.F., Okwuadi S., Sabin C., Amooty G., Brown V.S., Grace S.C., Emery V.C., and Griffiths P.D. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients. J. Infect. Dis. 189 (2004) 1355-1361
40. McSharry J.J., McDonough A., Olson B., Hallenberger S., Reefschlaeger J., Bender W., and Drusano G.L. Susceptibilities of human cytomegalovirus clinical isolates to BAY 38-4766, BAY 43-9695, and ganciclovir. Antimicrob. Agents Chemother. 45 (2001) 2925-2927
41. Merigan T.C., Renlund D.G., Keay S., Bristow M.R., Starnes V., O'Connell J.B., Resta S., Dunn D., Gamberg P., and Ratkovec R.M. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N. Engl. J. Med. 326 (1992) 1182-1186
42. Musch D.C., Martin D.F., Gordon J.F., Davis M.D., and Kuppermann B.D. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group. N. Engl. J. Med. 337 (1997) 83-90
43. Painter G.R., and Hostetler K.Y. Design and development of oral drugs for the prophylaxis and treatment of smallpox infection. Trends Biotechnol. 22 (2004) 423-427
44. Pass R.F. Epidemiology and transmission of cytomegalovirus. J. Infect. Dis. 152 (1985) 10-16
45. Paya C., Humar A., Dominguez E., Washburn K., Blumberg E., Alexander B., Freeman R., Heaton N., Pescovitz M.D., and Valganciclovir Solid Organ Transplant Study Group. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant. 4 (2004) 611-620
46. Razonable R.R., Brown R.A., Humar A., Covington E., Alecock E., Paya C.V., and PV16000 Study Group. Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease. J. Infect. Dis. 192 (2005) 1331-1339
47. ® management recommendations]. Herpes 11 (2004) 77-86
48. Reefschlaeger J., Bender W., Hallenberger S., Weber O., Eckenberg P., Goldmann S., Haerter M., Buerger I., Trappe J., Herrington J.A., Haebich D., and Ruebsamen-Waigmann H. Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action. J. Antimicrob. Chemother. 48 (2001) 757-767
49. Reusser P., Einsele H., Lee J., Volin L., Rovira M., Engelhard D., Finke J., Cordonnier C., Link H., and Ljungman P. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 99 (2002) 1159-1164
50. Ross S.A., and Boppana S.B. Congenital cytomegalovirus infection: outcome and diagnosis. Semin. Pediatr. Infect. Dis. 16 (2004) 44-49
51. Schleiss M.R., Bernstein D.I., McVoy M.A., Stroup G., Bravo F., Creasy B., McGregor A., Henninger K., and Hallenberger S. The non-nucleoside antiviral, BAY 38-4766, protects against cytomegalovirus (CMV) disease and mortality in immunocompromised guinea pigs. Antiviral Res. 65 (2005) 35-43
52. Schleiss M.R., and Heineman T.C. Progress toward an elusive goal: current status of cytomegalovirus vaccines. Expert Rev. Vaccines 4 (2005) 381-406
53. Singh N. Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implications for preventive strategies. J. Clin. Virol. 35 (2006) 474-477
54. Sullivan V., Talarico C.L., Stanat S.C., Davis M., Coen D.M., and Biron K.K. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 358 (1992) 162-164
55. Townsend L.B., Devivar R.V., Turk S.R., Nassiri M.R., and Drach J.C. Design, synthesis, and antiviral activity of certain 2,5,6-trihalo-1-(beta-d-ribofuranosyl)benzimidazoles. J. Med. Chem. 38 (1995) 4098-4105
56. Underwood M.R., Ferris R.G., Selleseth D.W., Davis M.G., Drach J.C., Townsend L.B., Biron K.K., and Boyd F.L. Mechanism of action of the ribopyranoside benzimidazole GW275175X against human cytomegalovirus. Antimicrob. Agents Chemother. 48 (2004) 1647-1651
57. Underwood M.R., Harvey R.J., Stanat S.C., Hemphill M.L., Miller T., Drach J.C., Townsend L.B., and Biron K.K. Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product. J. Virol. 72 (1998) 717-725
58. Valcyte (valgancyclovir hydrochloride tablets) package insert. Roche Laboratories Inc., 2003.
59. Valtrex (valacyclovir hydrochloride caplets) package insert. GlaxoSmithKline Inc., 2005.
60. ViroPharma Inc., 2005a. ViroPharma announces presentation of Phase 1 clinical data for maribavir. Available: http://www.viropharma.com/ (accessed January 31, 2006).
61. ViroPharma Inc., 2005b. ViroPharma Completes Enrollment in Phase 2 clinical study of maribavir in bone marrow transplant patients. Available: http://www.viropharma.com/ (accessed January 31, 2006).
62. Vistide package insert, 1996. Vistide (cidofovir injection) package insert. Gilead Sciences Inc., 1996.
63. Wang L.H., Peck R.W., Yin Y., Allanson J., Wiggs R., and Wire M.B. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother. 47 (2003) 1334-1342
64. Weber O., Bender W., Eckenberg P., Goldmann S., Haerter M., Hallenberger S., Henninger K., Reefschlager J., Trappe J., Witt-Laido A., and Ruebsamen-Waigmann H. Inhibition of murine cytomegalovirus and human cytomegalovirus by a novel non-nucleosidic compound in vivo. Antiviral Res. 49 (2001) 179-189
65. Whitley R.J., Cloud G., Gruber W., Storch G.A., Demmler G.J., Jacobs R.F., Dankner W., Spector S.A., Starr S., Pass R.F., Stagno S., Britt W.J., Alford Jr. C., Soong S., Zhou X.J., Sherrill L., FitzGerald J.M., and Sommadossi J.P. Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J. Infect. Dis. 175 (1997) 1080-1086
66. Wolf D.G., Courcelle C.T., Prichard M.N., and Mocarski E.S. Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 1895-1900
67. Zacny V.L., Gershburg E., Davis M.G., Biron K.K., and Pagano J.S. Inhibition of Epstein-Barr virus replication by a benzimidazole l-riboside: novel antiviral mechanism of 5, 6-dichloro-2-(isopropylamino)-1-beta-l-ribofuranosyl-1H-benzimidazole. J. Virol. 73 (1999) 7271-7277